2015 American Transplant Congress
Post-Kidney Allograft Nephrectomy Anti-HLA Immunization Is Not Due to a Release of Anti-HLA Antibodies from the Failed Kidney
Background and aims: The reasons for the increased incidence of de novo anti-HLA donor specific antibodies (DSAs) that is observed after kidney allograft nephrectomy (NTx)…2015 American Transplant Congress
Intermittent High Dose Intravenous Immunoglobulin as Treatment for Donor Specific Antibodies in Renal Transplant Recipients
Background: Donor-specific HLA antibody (DSA) formation in post-renal transplant patients is associated with chronic rejection and graft failure. Previous studies in our population have indicated…2015 American Transplant Congress
Prediction of Acute Antibody Mediated Rejection in Antibody Incompatible Renal Transplantation Using Machine Learning for Wide Data
The dynamic field of renal transplantation is characterised by limited access to data, the high cost of equipment and underlying complexity of immunological responses to…2015 American Transplant Congress
Retrospective Cohort Study Concerning Efficacy and Safety of Bortezomib in Combination With Or Without Rituximab in Antibody Mediated Rejection in Renal Transplant Recipients
Charité Universitätsmedizin Berlin, Department of Nephrology, Berlin, Germany.
Treatment of antibody-mediated rejection (AMR) in renal transplant (tx) patients (pts) is still challenging and long-term outcome remains unsatisfying. Because plasma cells (PCs) are crucial…2015 American Transplant Congress
Husband to Wife Renal Transplants Are Associated With a Higher Risk of Early Antibody Mediated Rejection and Transplant Glomerulopathy
Patients with a low level preformed donor specific antibodies [DSA] with a negative FCXM/CDC cross match are at high risk of antibody mediated rejection [AMR]…2015 American Transplant Congress
CPRA Values Are Substantially Increased for Some Candidates Subsequent to Inclusion of Unacceptable C-locus (UA-C) Antigens While Listing Practices Remain Unchanged
1UNOS, Richmond; 2Emory University Hospital, Atlanta; 3Stanford University, Palo Alto.
Background: CPRA is the % of deceased donors expected to have one or more UAs with a given candidate. Prior to 12/5/13, candidates with UA-C…2015 American Transplant Congress
Immunoglobulin G Donor-Specific Anti-HLA Antibody Subclasses and Kidney Allograft Antibody-Mediated Injury
Experimental and clinical data suggest that antibodies have different pathogenicities according to their IgG subclasses. We investigated the association between IgG subclasses of circulating anti-HLA…2015 American Transplant Congress
De Novo Donor-Specific HLA Antibodies After Kidney Transplantation Are Associated With Donation After Circulatory Death and HLA-DQ Mismatch
Introduction: De novo donor-specific HLA-antibodies (dnDSA) have been associated with rejection and inferior kidney graft survival. The purpose of this study was to investigate the…2015 American Transplant Congress
C1q Reactivity and IgG Subtypes After HLA Antibody Removal Therapy With Carfilzomib in Thoracic Transplant Recipients
Univ of Pittsburgh, Pittsburgh.
Conventional therapies for antibody removal consisting of plasma exchange with IVIG and Rituximab are partially effective in desensitization protocols and for treatment of antibody mediated…2015 American Transplant Congress
A Specific Inhibitor of C1s, TNT003, Prevents Complement-Mediated Enhancement of Monocyte Adhesion to Endothelium in Response to HLA Antibodies
HLA antibody (Ab) mediated complement activation on endothelial cells (EC) is likely a critical driver of antibody-mediated inflammation. Production of complement anaphylatoxins by HLA antibodies…
American Transplant Congress abstracts